Headlines about Tocagen (NASDAQ:TOCA) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tocagen earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.1263661629812 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of brokerages have commented on TOCA. BidaskClub upgraded Tocagen from a “hold” rating to a “buy” rating in a research note on Saturday, March 17th. Zacks Investment Research upgraded Tocagen from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Wednesday, March 14th. Finally, ValuEngine upgraded Tocagen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $21.50.
Shares of TOCA stock traded up $0.24 during trading hours on Friday, hitting $12.64. The company’s stock had a trading volume of 99,454 shares, compared to its average volume of 112,310. Tocagen has a 12 month low of $8.60 and a 12 month high of $17.95. The firm has a market capitalization of $246.90 and a PE ratio of -2.21. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.05.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.